跳轉至內容
Merck
全部照片(2)

重要文件

HANG2MAG-12K

Millipore

MILLIPLEX® 人血管生成板2,HANG2MAG-12K

Angiogenesis Bead-Based Multiplex Assays using the Luminex technology enables the simultaneous analysis of multiple angiogenic biomarkers in human serum, plasma and cell culture samples.

登入查看組織和合約定價


About This Item

分類程式碼代碼:
12161503
eCl@ss:
32161000
NACRES:
NA.84

品質等級

物種活性

human

製造商/商標名

Milliplex®

assay range

accuracy: 88-97%
standard curve range: 137-100,000 pg/mL
(Thrombospondin-2)

standard curve range: 137-100,000 pg/mL
(sVEGFR2)

standard curve range: 137-100,000 pg/mL
(suPAR)

standard curve range: 14-10,000 pg/mL
(sAXL)

standard curve range: 14-10,000 pg/mL
(sHER3)

standard curve range: 14-10,000 pg/mL
(sVEGFR1)

standard curve range: 27-20,000 pg/mL
(sIL-6Rα)

standard curve range: 27-20,000 pg/mL
(sPECAM-1)

standard curve range: 27-20,000 pg/mL
(sTIE-2)

standard curve range: 274-200,000 pg/mL
(Angiostatin)

standard curve range: 274-200,000 pg/mL
(sE-Selectin)

standard curve range: 274-200,000 pg/mL
(sNeuropilin-1)

standard curve range: 41-30,000 pg/mL
(Osteopontin (OPN))

standard curve range: 41-30,000 pg/mL
(sEGFR)

standard curve range: 41-30,000 pg/mL
(sHER2)

standard curve range: 41-30,000 pg/mL
(sc-Kit/sSCFR)

standard curve range: 412-300,000 pg/mL
(sVEGFR3)

standard curve range: 69-50,000 pg/mL
(sHGFR)

standard curve range: 7-5,000 pg/mL
(PDGF-AB/BB)

技術

multiplexing: suitable

檢測方法

fluorometric (Luminex xMAP)

運輸包裝

wet ice

一般說明

血管生成是新血管网的发展,是正常生长和发育以及伤口愈合的关键过程,其动态平衡由血管生成因子和抑制剂的精细平衡维持。因此,血管生长不足或过度是许多疾病的基础,包括心血管疾病,糖尿病溃疡,黄斑变性和癌症。血管生成在肿瘤生长和转移中起着重要作用。

MILLIPLEX®人体血管生成磁珠面板2是一种20重试剂盒,用于同时定量血清,血浆,细胞培养样品和组织匀浆/裂解物中以下分析物的任何或全部:血管抑素、可溶性E-选择素(sE-Selectin)、骨桥蛋白(OPN)、血小板衍生生长因子-AB/BB(PDGF-AB/BB),可溶性血小板内皮细胞粘连分子-1(sPECAM-1)、血小板反应蛋白-2(TSP-2)、可溶性AXL(sAXL),可溶性c-kit/干细胞生长因子受体(sc-Kit/SCFR),可溶性表皮生长因子受体(sEGFR)†,可溶性人表皮生长因子受体2(sHer2),可溶性人表皮生长因子受体3(sHer3),可溶性肝细胞生长因子受体/c-Met(sHGFR/c-Met),可溶性IL-6Rα,可溶性神经纤毛蛋白1(sNRP-1),可溶性Tie-2(sTie-2),可溶性尿激酶型纤溶酶原激活剂受体(suPAR),可溶性血管内皮生长因子受体1(sVEGFR1),可溶性血管内皮生长因子受体2(sVEGFR2)和可溶性血管内皮生长因子受体3(sVEGFR3)。该试剂盒采用96孔格式,包含冻干标准混合物、两个内部检测质控品,可最多可测定38份样品,重复两次。

†针对活性位点的抗体导致优先结合未结合的EGFR。

Luminex® xMAP®平台使用磁珠免疫分析格式,以实现理想的速度和灵敏度,同时定量多种分析物,从而显著提高生产力,同时节省宝贵的样品量。

面板类型:循环癌症

應用

  • 分析物:血管抑素、可溶性AXL(sAXL),可溶性c-kit/干细胞生长因子受体(sc-kit/sCFR)、可溶性E-选择素(sE-Selectin)、可溶性表皮生长因子受体(sEGFR/sErbB1/sHER1)†,可溶性人表皮生长因子受体2(sHER2/sHER2/sERBB2)、可溶性人表皮生长因子受体3(sHER3/sHER3/sErbB3)、可溶性肝细胞生长因子受体(shGFR/c-Met/SC-Met)、可溶性IL-6Rα(IL-6Rα(可溶型)/sIL-6Rα),可溶性神经纤毛蛋白-1(sNRP-1),骨桥蛋白(OPN),血小板衍生生长因子-AB/BB(PDGF-AB/BB),可溶性血小板内皮细胞粘连分子-1(sPECAM-1/sCD31),血小板反应蛋白-2(TSP-2),可溶性Tie-2(sTie-2),可溶性尿激酶型纤溶酶原激活物受体(suPAR),可溶性血管内皮生长因子受体1(可溶性VEGFR1,sVEGFR1/sFlt-1),可溶性血管内皮生长因子受体2(可溶性VEGFR2/sVEGFR2/SKDR/sFlk-1),可溶性血管内皮生长因子受体3(可溶性VEGFR3/sVEGFR3/sFlt-4)。
  • †针对活性位点的抗体导致优先结合未结合的EGFR。
  • 推荐样品类型:人血清、血浆、细胞培养上清液和组织/细胞匀浆/裂解物
  • 推荐的样品稀释度:每孔25 μL 1:5稀释的血浆或血清;细胞培养上清液可以不稀释使用,也可以用适当的对照培养基稀释使用
  • 分析运行时间:在2-8°C下过夜(16-18小时)
  • 研究类别:癌症

特點和優勢

通过在此面板中选择可用的分析物来设计多重试剂盒。

其他說明

灵敏度:有关单个分析物的灵敏度,请参见试剂盒方案。
请联系技术服务部进行稀释度线性研究。

法律資訊

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

訊號詞

Danger

危險分類

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

標靶器官

Respiratory Tract

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Luka Roškar et al.
Journal of clinical medicine, 10(4) (2021-03-07)
Preoperative determination of the extent of endometrial cancer (EC) would avoid the complications associated with radical surgery. Screening of patients' plasma biomarkers might enable a more precise diagnosis of EC and a tailored treatment approach. This prospective case-control monocentric pilot
Sayuri Padayachee et al.
Nigerian journal of physiological sciences : official publication of the Physiological Society of Nigeria, 37(1), 29-34 (2022-08-11)
A dysregulation of angiogenic mediators has been implicated in HIV infection. Inconsistent data exists on highly active antiretroviral therapy (HAART) usage in pregnancy and its association with PE development. In view of the high prevalence of HIV infection and PE
Nicos Mitsides et al.
Nephron, 143(4), 234-242 (2019-09-13)
Progressive chronic kidney disease (CKD) inevitably leads to salt and water retention and disturbances in the macro-and microcirculation. We hypothesize that salt and water dysregulation in advanced CKD may be linked to inflammation and microvascular injury pathways. We studied 23
Juan Pablo Hinestrosa et al.
Communications medicine, 2, 29-29 (2022-05-24)
Detecting cancer at early stages significantly increases patient survival rates. Because lethal solid tumors often produce few symptoms before progressing to advanced, metastatic disease, diagnosis frequently occurs when surgical resection is no longer curative. One promising approach to detect early-stage

相關內容

The angiogenesis pathway is complex with many targets to analyze. Simultaneous quantification of multiple markers, with the MILLIPLEX® Human Angiogenesis/Growth Factor Panel 1, saves valuable resources. See how this panel was used to correlate angiogenesis biomarkers with early metastatic progression in NSCLC.

Cancer biomarker detection through MILLIPLEX® multiplex cancer assays can accelerate studies of tumorigenic processes helping advance cancer research.

Learn how multiplexing with MILLIPLEX® multiplex assays can help simplify cancer research by measuring multiple circulating biomarkers at once. Find multiplex panels to analyze JAK-STAT, mTOR, MAPK, SAPK, TGFβ signaling pathways, and more.

多重分析法可同時測量各種訊號傳導通路的多種生物標記,簡化癌症研究。

查看全部

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務